Sonelokimab for Biologic-Naive Psoriatic Arthritis

Sonelokimab for Biologic-Naive Psoriatic Arthritis
57%46%35%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 27 • YES 46.0%
MoonLake Immunotherapeutics AG ($MLTX)
No stock close$18.81$17.42$16.03May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 18 • MLTX $16.44May 19 • MLTX $16.37May 20 • MLTX $17.05May 21 • MLTX $18.47May 22 • MLTX $18.19May 26 • MLTX $18.23May 27 • MLTX $18.41

Will this trial show a positive result on Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle

Matched news2 items

All news
MLTX

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving HiSCR75 and up to 32% of patients achieving HiSCR100 An analysis

Trial Results • Phase 3Matched sonelokimab, psoriatic, arthritis, adults
MLTX

MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results

In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12 Consistently, other clinical and imaging scores also showed improvements of 80+% by week 12 for patients treated

Trial Results • Phase 2Matched sonelokimab, arthritis